Drug Approval | December 11, 2025
Roche secures European nod for Gazyva/Gazyvaro in Lupus Nephritis patients
The approval follows strong results from Roche’s phase II NOBILITY and phase III REGENCY studies
The approval follows strong results from Roche’s phase II NOBILITY and phase III REGENCY studies
Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
The collaboration will establish the MUMPMP–Agilent BioDiscovery Hub
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
The project focuses on recovering high-quality polycarbonate, a valuable polymer material used in the construction of the filters
The study met its primary endpoint and all 11 secondary efficacy endpoints
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
Captured microbes are then neutralized on engineered microbicidal surfaces
76 of 180 long COVID-associated genes also linked to ME
DUPLEX’s two-compartment, PVC- and DEHP-free design keeps medication and diluent separate until activation
Subscribe To Our Newsletter & Stay Updated
